21 hrs ago
Critical Alerts For Arrowhead Research, Isis Pharmaceuticals,...
To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
Tue Aug 26, 2014
Tuesday's ETF Movers: XBI, XLU
In trading on Tuesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.2% on the day.
Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets
Achillion Pharmaceuticals and Arrowhead Research were up sharply Tuesday after an analyst said the pair of drug development companies could become takeover targets.
Tue Aug 12, 2014
Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520
Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an update on the Phase 2a study of ARC-520, its RNAi-based candidate for the treatment of chronic hepatitis B infection.
Arrowhead Research Corp (ARWR) Announces Quarterly Earnings Results, Hits Estimates
Arrowhead Research Corp posted its quarterly earnings results on Tuesday. The company reported earnings per share for the quarter, meeting the consensus estimate of , Analyst Ratings Network reports.
Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential
There are 350M-400M people infected with chronic hepatitis B . CEO says functional cure for hepatitis B would be "transformational".
Thu Jul 31, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
Fiscal 2014 Second Quar... )--Apartment Investment and Management Company announced today its second quarter 2014 results.